Actelion Pharmaceuticals Ltd : Actelion appoints André C. Muller as new Chief Financial Officer and member of Actelion's

Actelion Pharmaceuticals Ltd : Actelion appoints André C. Muller as new Chief
 Financial Officer and member of Actelion's Executive Committee - succeeding
                Andrew J. Oakley - effective 01 September 2013

Actelion Pharmaceuticals Ltd / Actelion appoints André C. Muller as new Chief
Financial Officer and member of Actelion's Executive Committee - succeeding
Andrew J. Oakley - effective 01 September 2013 . Processed and transmitted by
Thomson Reuters ONE. The issuer is solely responsible for the content of this
announcement.

ALLSCHWIL/BASEL, SWITZERLAND- 27 August 2013 -Actelion Ltd (SIX: ATLN)
announced today that it has appointed André C. Muller (49) as the company's
Chief Financial Officer and member of Actelion's Executive Committee (AEC). He
succeeds AndrewJ.Oakley (51), who will focus on opportunities outside
Actelion. Mr. Muller will take office on01 September2013.

Jean-Paul Clozel, M.D. and Chief Executive Officer of Actelion, commented: "I
am pleased to welcome André Muller as Chief Financial Officer at Actelion. He
brings vast experience as a pharmaceutical finance executive and I am
confident that André will make a significant contribution to Actelion's
continued success."

André C. Muller is a French citizen joining Actelion from Pierre Fabre SA, an
international pharmaceutical and cosmetic group, where he held various
positions from 1994 until 2011, most recently as Chief Financial Officer. He
holds an MBA from the Business School EM, Lyon

Thanking Andrew Oakley for his contribution, Jean-Paul Clozel said: "Over the
last decade Andrew has led Actelion's finance office, supporting our
significant expansion. We wish him every success for his future."

                                     ###

NOTES TO THE EDITOR

ABOUT ACTELION LTD
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer® (bosentan), an
orally available dual endothelin receptor antagonist, has been approved as a
therapy for pulmonary arterial hypertension. Actelion markets Tracleer through
its own subsidiaries in key markets worldwide, including the United States
(based in South San Francisco), the European Union, Japan, Canada, Australia
and Switzerland. Actelion, founded in late 1997, is a leading player in
innovative science related to the endothelium - the single layer of cells
separating every blood vessel from the blood stream. Actelion's over 2,300
employees focus on the discovery, development and marketing of innovative
drugs for significant unmet medical needs. Actelion shares are traded on the
SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index
SMI (Swiss Market Index SMI®).

For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com

The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "are expected to", "will", "will continue", "should", "would be",
"seeks", "pending" or "anticipates" or similar expressions, or by discussions
of strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described
herein as anticipated, believed, estimated or expected.

Press Release PDF

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
HUG#1724919

--- End of Message ---

Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;
 
Press spacebar to pause and continue. Press esc to stop.